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Abstract: A flexible methacrylate powder dressing (Altrazeal®) transforms into a wound 
contour conforming matrix once in contact with wound exudate. We hypothesised that it 
may also serve as a drug delivery vehicle for antiseptics. The antimicrobial efficacy and 
influence on bacterial growth kinetics in combination with three antiseptics was 
investigated in an in vitro porcine wound model. Standardized in vitro wounds were 
contaminated with Staphylococcus aureus (MRSA; ATCC 33591) and divided into  
six groups: no dressing (negative control), methacrylate dressing alone, and combinations 
with application of 0.02% Polyhexamethylene Biguanide (PHMB), 0.4% PHMB,  
0.1% PHMB + 0.1% betaine, 7.7 mg/mL Povidone-iodine (PVP-iodine), and 0.1%  
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Octenidine-dihydrochloride (OCT) + 2% phenoxyethanol. Bacterial load per gram tissue 
was measured over five days. The highest reduction was observed with PVP-iodine at 24 h to 
log10 1.43 cfu/g, followed by OCT at 48 h to log10 2.41 cfu/g. Whilst 0.02% PHMB resulted 
in a stable bacterial load over 120 h to log10 4.00 cfu/g over 120 h, 0.1% PHMB + 0.1% 
betaine inhibited growth during the first 48 h, with slightly increasing bacterial numbers up 
to log10 5.38 cfu/g at 120 h. These results indicate that this flexible methacrylate dressing 
can be loaded with various antiseptics serving as drug delivery system. Depending on the 
selected combination, an individually shaped and controlled antibacterial effect may be 
achieved using the same type of wound dressing. 
Keywords: wound dressing; biofilm; drug delivery; antiseptic; polyhexanide;  
povidone-iodine; octenidine-dihydrochloride; methacrylate; Altrazeal; Prontosan C; 
Octenisept; Braunol 
 
1. Introduction 
An infection occurs, following contamination and colonization by bacteria, when a wound and 
surrounding tissue is invaded with a subsequent inflammatory reaction. An infection may remain 
localized or may generalize. The occurrence of wound infection depends on the underlying condition 
of the patient and associated immune response, the amount of primary contamination and on the 
virulence of the involved bacteria [1]. 
Wound infection may impede the process of healing and eventually lead to severe and life 
threatening complications. Despite low prevalence of multi-resistant Gram-positive pathogens in 
Austria, wounds have been identified as primary source of infection in at least 1.6% of hospitalized 
patients with multi-resistant Staphylococcus aureus (MRSA) bacteremia [2]. A study conducted in 
Brazil demonstrated that in patients with pressure ulcers stage II 65% of wounds were colonized or 
infected with multidrug-resistant organisms, thereof 33% with Gr-negative bacilli, 21% with MRSA, 
and 47% with both [3]. Therefore, promoting the healing process and protecting a wound from 
potential contamination with pathogenic and/or multi-resistant bacteria is imperative for prevention of 
wound infection. Wound dressing selection depends on the type of wound and its etiology, its severity, 
its condition, particularly the level of contamination and infection, and its anatomic location. However, 
all dressings are intended to protect a wound from mechanical and environmental injuries, from 
microbial contamination, and eventually to promote wound healing. Over the past three decades, an 
increasing number of different wound dressing types and categories have been developed. In brief, 
modern wound dressings may be categorized as film, pad dressings with a functional or non-adherent 
island, adherent, or moist dressings such as hydrogel and hydrocolloid dressings, and absorbent 
dressings such as alginates, foam dressings, or super-absorbing dressings [4] In addition, wound 
dressings may be non-antimicrobial or may have an antimicrobial component, such as povidone iodine, 
chlorhexidine, silver or polyhexamethylene biguanide (PHMB) [5].  
Today, and particularly in light of a global increase of antibiotic resistant bacteria [6,7], 
antimicrobial dressings can play an important role in wound care in the prevention and management of 
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infection. While universal agreement on clinical indicators relevant to intervention with antimicrobial 
dressings remain illusive [8,9], it is important to remember that all antimicrobial wound dressings have 
different physical and pharmacological properties. These include: the type and amount of antimicrobial 
they release, the duration and mode of antimicrobial action, the dressing’s ability to manage varying 
volumes of wound exudate, to decrease malodour or pain. Apart from the specific, physical characteristics 
of different antimicrobial dressings, the most widely used agents in antimicrobial dressings are various 
forms of silver (ionic, elementary, nano-crystalline, or silver salts) [10], iodine [11], and increasingly 
medical honey. Some antimicrobial dressings contain PHMB [12,13], others chlorhexidine, and so far, 
no commercially available wound dressing contains the antiseptic octenidine-dihydrochloride (OCT) [14] 
yet. The available range of these different dressings in clinical practice means that large volumes of 
dressings need to be kept in stock. Furthermore, medical care providers are restricted in their practice 
to limited numbers of antimicrobial compounds, and have little possibility to alter the pharmacokinetic 
release profile of the applied antimicrobial. Therefore, a dressing would be beneficial, which allows 
medical professionals to decide whether the dressing shall be applied as an antimicrobial or  
non-antimicrobial dressing, and which antimicrobial compound should be used.  
Recently, a flexible methacrylate dressing (Altrazeal®, Uluru Inc., Addison, TX, USA) has been 
introduced [15]. This dressing, which comes as a powder and transforms into a wound contour 
conforming matrix once in contact to wound exudate, is based on dehydrated hydrogel modified into 
60–65 µm small particles containing a poly-2-hydroxyethyl-/poly-2-hydroxypropyl (pHEMA/ 
pHPMA) -methacrylate backbone and terminal hydroxyl group. This polymer is a member of the 
family of hydrophilic polymers that contain a covalent methacrylate backbone with a hydroxyl 
aliphatic side chain, resembling very much the polymers used in soft contact lenses. The dressing can 
be directly applied into a wound and transforms in presence of wound exudate, or can be hydrated with 
saline or other sterile solutions, resulting in transformation into a wound contour conforming flexible 
dressing. After aggregation, capillary channels of approximately 7 nm width wick exudate from the 
wound surface through a high moisture vapor transpiration rate, of approximately 12,000 mL/m2/24 h, 
whilst at the same time promoting a moist wound environment for healing [16]. The aggregated 
dressing contains approximately 68% water, which is similar to the water content of the skin  
(72%–74%), further increasing its biological compatibility. 
Because of the inert nature of the aggregated polymer whereby only the  
pHEMA/pHPMA-methacrylate particles react with each other, we hypothesised that this novel 
dressing may be an ideal candidate to serve as a drug delivery vehicle for various cationic and anionic 
wound antiseptics. Therefore, the antimicrobial efficacy of this dressing, in combination with five 
antimicrobial wound irrigation solutions/antiseptics, and its combined influence on bacterial growth 
kinetics was investigated in this study using an in vitro wound model. 
2. Results and Discussion 
2.1. Results for Negative Control and Non-Antimicrobial Methacrylate Dressing  
Without any dressing, the mean Staphylococcus aureus load per gram tissue started at log10 4.02 cfu/g 
tissue, and followed a typical bacterial growth curve increasing to a mean load of log10 7.07 cfu/g 
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tissue at 120 h. Without loading of any antimicrobial compound the methacrylate dressing did not 
prevent bacterial growth; however, it decreased multiplication of bacterial numbers per gram tissue to 
the magnitude of 1.5 log10 compared with the negative control. 
2.2. Results for Methacrylate Dressing Loaded with Antimicrobial Compounds 
The highest bacterial reduction was observed with PVP-iodine at 24 h to log10 1.43 cfu/g tissue, 
followed by OCT at 48 h to log10 2.41 cfu/g tissue. 
In combination with PHMB the dressing resulted in different bacterial kinetics: 0.02% PHMB 
resulted in a stable bacterial load at a mean log10 4.00 cfu/g tissue over 120 h; 0.1% PHMB + 0.1% 
betaine inhibited growth during the first 48 h, with slightly increasing bacterial numbers up to log10 
5.38 cfu/g tissue at 120 h; 0.4% PHMB resulted in a kinetic curve similar to OCT with approximately 
0.5–1.5 log10 higher bacterial counts over all time periods. Detailed results are summarized in Table 1.  
Table 1. Kinetics of S. aureus (ATCC 33591) under a methacrylate dressing alone and in 
combination with five antiseptics over five days after a single application of the 
antimicrobial compound. 
Dressing +/− antiseptic  
or no dressing  
Mean bacterial colony forming units (log10) per gram tissue (±1 SD) after 
0 h 24 h 48 h 72 h 96 h 120 h 
Negative control 4.02 (± 2.67) 7.12 (± 6.52) 8.61 (± 7.43) 8.26 (± 7.12) 7.56 (± 6.59) 7.07 (± 6.89)  
Methacrylate dressing 4.02 (± 2.67) 6.11 (± 5.40) 7.02 (± 7.11) 7.56 (± 6.71) 7.05 (± 5.80) 6.90 (± 6.65) 
0.02% PHMB a 4.01 (± 2.46) 3.93 (± 2.85) 3.98 (± 2.93) 3.87 (± 2.94) 4.01 (± 2.83) 4.01 (± 2.71) 
0.1% PHMB a + 0.1% betaine b 4.03 (± 2.67) 4.12 (± 3.63) 4.20 (± 3.54) 4.96 (± 3.76) 4.95 (± 3.71) 5.38 (± 4.96) 
0.4% PHMB a 4.01 (± 2.32) 3.39 (± 2.68) 3.29 (± 2.10) 3.63 (± 2.87) 3.84 (± 2.35) 3.79 (± 2.26) 
7.7 mg/mL PVP-I c 4.02 (± 2.67) 1.43 (± 0.91) 1.84 (± 1.01) 2.45 (± 1.64) 3.14 (± 1.98) 3.29 (± 1.89) 
0.1% OCT d + 2% PE e 4.01 (± 1.91) 3.14 (± 1.79) 2.41 (± 1.69) 2.78 (± 1.49) 2.89 (± 1.74) 3.24 (± 2.02) 
a PHMB = Polyhexamethylene Biguanide; b Betaine = Undecylenamidopropyl-Betain; c PVP-I = Povidone-iodine;  
d OCT = Octenidine-dihydrochloride; e PE = Phenoxyethanol; Data represent the means (±1 SD) of four independent 
experiments each after standard contamination with log10 7.00 cfu S. aureus per gram tissue. 
The data indicate that the test conditions were stable and reproducible. In particular, the initial  
bio-burden per gram of tissue after contamination with an inoculum of log10 7.00 cfu/g yielded a 
comparable S. aureus load of approximately log10 4.00 cfu/g tissue in all test essays. Although the 
individual results seem to show a wide distribution, and particularly for the negative control assay with 
higher individual cfu-counts, the standard deviations always ranged 1–2 log10 below the respective 
mean results. Such variations are frequently observed in biological systems [17–20] and are to be 
expected. Most importantly, the results of this experimental study establish the possibility to load a 
methacrylate dressing with various antiseptics, which are released into the surrounding tissue. The 
presence of the antimicrobial compound in tissue was indirectly demonstrated by the reduced bacterial 
counts per gram of tissue, as no other possibility exists explaining the lower cfu/ g tissue counts of  
S. aureus in the respective essays. The detailed bacterial growth kinetics are shown in Figure 1. 
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Figure 1. Kill-time study and bacterial growth kinetics of S. aureus (ATCC 33591) in 
presence and absence of a methacrylate dressing with and without single loading of 
antiseptics over five days application. Bacterial counts expressed as absolute numbers per 
gram of tissue. Data represent the means of four independent experiments each after 
standard contamination with 1.0 × 107 cfu S. aureus per gram tissue. Results are depicted 
using absolute numbers. 
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Interestingly, the use of methacrylate polymers in wound care is not totally new and was proposed 
some three decades earlier. Migliaresi et al. [21] reported on a polybutadiene layer to which  
poly(2-hydroxyethyl methacrylate) (pHEMA) was thermally grafted. The authors suggested the use of 
such compound materials to be used as burn wound cover, since the presence of polybutadiene 
increased the tensile properties of the dressing and prevented water diffusion while it did not affect the 
oxygen permeability of the pHEMA. The use of pHEMA with other admixtures such as polyethylene 
glycol-400 (PEG), including antimicrobial additives such as silver sulfadiazine, silver nitrate, 
gentamicin or nitrofurazone in burn wounds was also proposed [22]. Experimental and clinical studies 
showed that adding antimicrobial compounds to a pHEMA base did not only reduce the bacterial count 
in burn wounds, but also exhibited a pain release effect in patients [22–24]. After some years of 
absence, methacrylate polymers shift again into attention as material base for wound dressings. 
Recently, electrospinned zwitterionic poly(sulfobetaine methacrylate) (pSBMA) was investigated to be 
used as a superabsorbent and non-adherent wound dressing [25], including its used with antimicrobial 
compounds [26,27]. However, while promising, all these previous approaches have either used woven 
polymers in form of a 2-dimensional dressing or in form of a composite gel. The investigated 
methacrylate dressing studied in our experiments goes one step further since it can be applied directly 
into the wound bed as a pure and inert pHEMA/ pHPMA powder, which than transforms into a 
polymer matrix allowing complete wound bed contouring and easy removal.  
However, there are some aspects which need to be highlighted. Firstly, the kill-time curves 
represent the bacterial growth kinetics in non-vital and undisturbed tissue. Influencing conditions in 
clinical wounds may be different, particularly pertaining to mechanical pressure, temperature, and 
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surrounding pH. Secondly, it would be a misinterpretation to conclude that PVP-iodine is the most 
effective antiseptic, or that 0.1% PHMB with 0.1% betaine is the least effective antimicrobial 
compound in this study. Selection of antiseptics in wound care depend on a number of factors such as: 
identification of pathogens, the clinical condition of the patient and the etiology of a specific wound, 
and the health care provider’s intention to apply an antiseptic therapeutically, either to treat a localized 
infected wound, or to prevent a wound from becoming infected. In this regard, the methacrylate 
dressing may be useful in not only serving as a wound dressing, but also as a drug delivery matrix for 
the most appropriate antimicrobial compound. Hence, the dressing permits application as a non-antimicrobial 
dressing, if antimicrobial action is not required. It also may be used as an antimicrobial dressing [28] to 
protect a non-infected wound from infection by loading it with, for example 0.1% PHMB + 0.1% 
betaine, or to eradicate colonizing microorganisms with, for example 0.4% PHMB, or to treat infected 
wounds by rapid kill of pathogenic microorganisms with, for example OCT or PVP-iodine. Following 
this algorithm, a health care provider may offer patients an individual, tailored, wound treatment based 
on individual clinical demands. 
Thirdly, it may be assumed that many of the bacteria in the model may have been attached to tissue 
and eventually may have formed biofilms, which reduces their antimicrobial susceptibility. Therefore, 
the antimicrobial efficacy of various antiseptics in tissue was lower than what is seen in quantitative 
suspension tests, where antiseptics get in contact to planktonic bacteria instead of their sessile form. 
Yet, the results of the direct bacterial reduction indicate that a methacrylate dressing loaded with 
antiseptics may have an effect even on sessile bacteria embedded in biofilm. However, the limitation 
of the experiment was that presence of biofilms was not demonstrated by additional staining techniques.  
And finally, the experimental design of this study investigated only the kill-time kinetic after one 
single application of an antiseptic. Repeated administration of antiseptics most likely would have 
yielded for all tested compounds far lower bacterial counts over all time points. However, the clinical 
relevance of such strategy for wound care management to use a methacrylate dressing loaded with 
antiseptics remains unknown and requires future research. 
3. Experimental Section  
3.1. In-Vitro Test Model 
For the in vitro test model, fresh raw porcine meat of comparable size (30 × 30 × 30 cm) was used 
for each experiment. A standard wound of 4 × 4 × 1 cm was cut into the pork meat using sterile 
instruments and maintaining aseptic conditions. The wound was then experimentally contaminated 
with a bacterial test-suspension and incubated for 8 h at 35 °C. 
3.2. Preparation of the Test-Suspension and Artificial Contamination of the Wound 
For the test-suspension, a clinical isolate of a well described Methicillin-resistant Staphylococcus 
aureus (MRSA; strain ATCC 33591) was used. From an overnight culture on Brain Heart Infusion 
(BHI) agar plates an optical density (OD) of McFarland 0.5 was set using a VITEK 2 Densi-check 
(bioMérieux, Marcy l'Etoile, France). Using sterile 0.9% NaCl as suspension solution, the final 
bacterial count was set to 1.0 × 107 (log10 7.00) cfu/mL. The artificial wounds were then contaminated 
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with 1 mL of the test-suspension and incubated at 37 ± 1 °C for 8 h. After the incubation period the 
rest of the test-suspension was removed without contaminating the surrounding tissue and 4 biopsies of 
the wounds (each 5 mm diameter, 5 mm depth) were taken, resulting in a reproducible wound 
colonization of 1.0 × 104 (log10 4.00) cfu/g of tissue (Table 1). 
3.3. Preparation of Test Model and Processing of Tissue Biopsies 
Wounds were treated with no dressing (negative control), the methacrylate test dressing (Altrazeal®; 
Uluru Inc., Addison, TX, USA) alone, and in combination with 0.02% PHMB (20% Cosmocil®;  
Arch Chemicals Inc., Norwalk, CT, USA), 0.1% PHMB + 0.1% betaine (Prontosan C®; B. Braun 
Melsungen AG, Melsungen, Germany), 0.4% PHMB (Lavasept®; B. Braun Melsungen AG, Melsungen, 
Germany), 7.7 mg/mL PVP-iodine (Braunol®; B. Braun Melsungen AG, Melsungen, Germany), and 0.1% 
OCT + 2% phenoxyethanol (Octenisept®; Schülke & Mayr GmbH, Norderstedt, Germany), respectively. 
Bacterial loads per gram of tissue were measured after 0 h, 24 h, 48 h, 72 h, 96 h and 120 h. All 
experiments were conducted in quadruplicate. One wound without any dressing served as negative 
control to assess the normal bacterial kinetic of the in vitro wound model. After removal of the test 
dressing, four tissue biopsies each were taken, weighed and homogenized using 0.9% NaCl in addition 
to 0.6 µg/mL oxacillin. Bacterial numbers in the homogenized solutions were then determined using 
microtiter-plates filled with BHI broth containing 75 mg/mL aztreonam. The number of bacteria was 
noted as absolute count or log10 cfu/g tissue, whenever appropriate. The means together with standard 
deviation (± SD) were calculated and set as the starting point for the wound colonization. 
4. Conclusions  
This study demonstrates that a methacrylate dressing applied into an experimental wound as a 
powder, which then transforms into a flexible, wound-contouring dressing, can be combined with a 
number of antiseptics and serve as a drug delivery system for antimicrobial compounds. Depending on 
the selected moisturizing solution, an individually tailored and controlled non-antimicrobial or 
antimicrobial effect may be achieved using the same type of wound dressing. This opens new 
possibilities for topical antimicrobial treatment and prophylactic strategies in wound care management. 
It needs to be elucidated in future studies, as to whether these effects correlate with the clinical  
(in vitro) situation in infected or contaminated wounds. 
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